|Bid||4.910 x 500|
|Ask||4.920 x 700|
|Day's Range||4.810 - 5.030|
|52 Week Range||3.950 - 7.390|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Plans are for the combined company to be based in Exton, Pa. Two major shareholders of one of the companies oppose the deal.
Great Point Partners isn’t the only significant BioCryst shareholder that plans to vote against the Durham company’s planned merger with Exton, Pennsylvania-based Idera Pharmaceuticals.
'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.
Examining BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...
The Durham, North Carolina-based company said it had a loss of 20 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Durham's BioCryst Pharmaceuticals (Nasdaq: BCRX) and Exton, Pennsylvania-based Idera Pharmaceuticals (Nasdaq: IDRA) have outlined more specifics on what company leaders view as benefits of the merger. ...
Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.
On Monday, Cambridge-based Idera Pharmaceuticals announced plans to merge with BioCryst Pharmaceuticals, based in Durham, North Carolina, with the resulting company to be based in Exton, Pennsylvania. As part of the all-stock deal, a spokesman for Idera (IDRA) said Monday that eventually that company's current Cambridge headquarters, where 36 employees now work, would be closed, as would the Durham one. “Over time, the company will move toward the thoughtful consolidation from four sites to two — Exton, Pennsylvania and our research facilities in Birmingham, Alabama," said Robert Doody, Idera's vice president of investor relations, in an email to the Business Journal.
Durham’s BioCryst Pharmaceuticals (BCRX) will merge with Exton, Pennsylvania-based Idera Pharmaceuticals (IDRA) in an all-stock deal, the companies said Monday. Idera’s CEO Vincent Milano will lead the combined company, with BioCryst’s CEO Jon Stonehouse serving as a member of its board of directors. Milano will also serve as a member of the combined company’s board, which will be chaired by Robert Ingram, pharmaceutical executive and former CEO and Chairman of Glaxo/Wellcome.
BioCryst Pharmaceuticals Inc. and Idera Pharmaceuticals Inc. announced early Monday plans to merge into a rare disease company. Shares of both companies were halted in premarket trade. Under the deal, ...
Categories: Yahoo FinanceGet free summary analysis BioCryst Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of BioCryst Pharmaceuticals, Inc. – Repligen Corporation, Sarepta Therapeutics, Inc., Novavax, Inc., Aviragen Therapeutics Inc, Celldex Therapeutics, Inc., Gilead Sciences, Inc., NanoViricides, Inc., Emergent BioSolutions Inc. and GlaxoSmithKline plc ... Read more (Read more...)
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives BioCryst Pharmaceuticals, Inc. a score of 25. Our analysis is based on comparing BioCryst Pharmaceuticals, Inc. with the following peers – Repligen Corporation, Sarepta Therapeutics, Inc., Novavax, Inc., Aviragen Therapeutics Inc, Celldex Therapeutics, Inc., Gilead Sciences, Inc., NanoViricides, Inc., CEL-SCI Corporation, Emergent BioSolutions Inc. and GlaxoSmithKline plc ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioCryst Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
Investors are always looking for growth in small-cap stocks like BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), with a market cap of USD $460.19M. However, an important fact which most ignore is: howRead More...
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...
The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.